Skip to Main Content

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Conditions

Immune System

Phase III

What is the purpose of this trial?

To evaluate the long-term safety and tolerability of seladelpar.

  • Trial with
    CymaBay Therapeutics, Inc.
  • Start Date
    07/27/2021
  • End Date
    12/31/2024

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/09/2021
  • Study HIC
    #2000030598